Zydus Lifesciences Ltd. has synthesized co-crystals of saroglitazar and chitosan acting as triglyceride-lowering agents found to be potentially useful for the treatment of dyslipidemia and hyperglycemia.

Rin Institute Inc. has disclosed antibody-drug conjugates consisting of an antibody targeting insoluble fibrin conjugated to MMAE through a plasmin-cleavable linker reported to be useful for the treatment of cancer.

Farsight Medical Technology (Shanghai) Co. Ltd. has identified cyclosporin analogues found to be potentially useful for the treatment of hepatitis B viral infections.

Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have described tachykinin NK3 receptor antagonists that are potentially useful for the treatment of menopausal symptoms, polycystic ovarian syndrome, uterine fibroids (myoma), schizophrenia, irritable bowel syndrome and breast cancer.

Janssen Pharmaceutica NV has synthesized endosomal/lysosomal proton channel TMEM175 activators reported to be useful for the treatment of Parkinson’s disease.

Evotec International GmbH has reported new prodrugs of NLRP3 inflammasome inhibitors potentially useful for the treatment of inflammation, asthma, hypertension, myocardial infarction, neurological disorders, silicosis, graft-vs.-host and metabolic diseases.

Asahi Kasei Therapeutics Corp. has identified new tumor necrosis factor receptor superfamily member 1A (TNFRSF1A; TNFR1; p55; CD120a) antagonists potentially useful for the treatment of rheumatoid arthritis, psoriasis, ankylosing spondylitis, hidradenitis suppurativa, ulcerative colitis and Crohn's disease.

Tennor Therapeutics Ltd. has patented new compounds potentially useful for the treatment of bacterial infections.

Brightgene Bio-Medical Technology Co. Ltd. has divulged new gastric inhibitory polypeptide receptor (GIPR), glucagon receptor (GCGR) and glucagon-like peptide 1 receptor (GLP-1R) agonists potentially useful for the treatment of neurodegeneration, bone, metabolic and cardiovascular disorders.

Zhejiang Jingke Pharmaceuticals Co. Ltd. has disclosed new deuterated isoindoline compounds acting as sigma non-opioid intracellular receptor 1 (SIGMAR1) and sigma intracellular receptor 2 (TMEM97) ligands. They are described as potentially useful for the treatment of multiple sclerosis, amyotrophic lateral sclerosis, dry macular degeneration, rheumatoid arthritis, asthma, Alzheimer's and Parkinson's disease.